Ingenza announces extension of collaboration with Syngenta

NewsGuard 100/100 Score

Industrial biotech specialist Ingenza has announced that its collaboration with Syngenta for work on efficient technologies to support the development of crop protection products has been extended. The continuation of this project capitalizes on Ingenza’s proprietary in ABLE® suite of gene expression, protein expression and microbial strain development capabilities, and demonstrates the company’s expertise in synthetic biology.

Ingenza Molecular Biologists; Research Assistant, Louis Marlow and Senior Scientist, Stephen McColm

Dr Ian Fotheringham, Managing Director at Ingenza, said:

We are delighted by the continued success of this collaboration. Our innovative technologies are an excellent fit for Syngenta’s leading position in agricultural biotechnology, and we look forward to continuing our partnership, working towards sustainable technologies that address the challenges facing global agriculture and food security.”

Dr Robert Harris, from Syngenta, added:

It has been a pleasure to work with the Ingenza team, and the success of our collaboration so far clearly shows how working with like-minded biotech partners helps to drive innovation forward. We are excited about the next phase of the project and look forward to realizing the potential of this technology”.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.